Table 2. VWF measurements and BT before... | American Society of Hematology

Table 2.

VWF measurements and BT before and after DDAVP in selected patients with type 2A VWD

	Time after DDAVP, h	VWF:RCo, U/dL	VWF:Ag, U/dL	VWF:RCo/Ag ratio	Bleeding time, min
Normal values (range)		110 ± 35 (46-202)	112 ± 36 (50-218)	0.99 ± 0.23 (0.63-1.75)	5 ± 2 (3-7)
Patient with S1506L, group 1	Baseline	<6	22	0.27	>30
	0.5	14	44	0.32	>30
	1	22	68	0.32	>30
	2	24	77	0.29	>30
	4	14	64	0.22	>30
Patient with R1597W, group 2	Baseline	6	31	0.19	>30
	0.5	65	100	0.65	NT
	1	60	134	0.45	6.30
	2	53	112	0.47	12
	4	36	96	0.37	15
Patient with G1629R, group 2	Baseline	30	100	0.30	>30
	0.5	67	190	0.35	NT
	1	79	236	0.33	10
	2	60	232	0.26	20
	4	62	252	0.25	>30
Patient with V1665E, group 1	Baseline	<6	22	0.27	>30
	1	10	91	0.11	>30
	2	13	95	0.14	>30
	4	10	104	0.10	>30

	Time after DDAVP, h	VWF:RCo, U/dL	VWF:Ag, U/dL	VWF:RCo/Ag ratio	Bleeding time, min
Normal values (range)		110 ± 35 (46-202)	112 ± 36 (50-218)	0.99 ± 0.23 (0.63-1.75)	5 ± 2 (3-7)
Patient with S1506L, group 1	Baseline	<6	22	0.27	>30
	0.5	14	44	0.32	>30
	1	22	68	0.32	>30
	2	24	77	0.29	>30
	4	14	64	0.22	>30
Patient with R1597W, group 2	Baseline	6	31	0.19	>30
	0.5	65	100	0.65	NT
	1	60	134	0.45	6.30
	2	53	112	0.47	12
	4	36	96	0.37	15
Patient with G1629R, group 2	Baseline	30	100	0.30	>30
	0.5	67	190	0.35	NT
	1	79	236	0.33	10
	2	60	232	0.26	20
	4	62	252	0.25	>30
Patient with V1665E, group 1	Baseline	<6	22	0.27	>30
	1	10	91	0.11	>30
	2	13	95	0.14	>30
	4	10	104	0.10	>30